BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
1/16/2026 11:31:18 AM | Browse: 72 | Download: 196
 |
Received |
|
2025-07-02 02:00 |
|
Peer-Review Started |
|
2025-07-02 02:00 |
|
First Decision by Editorial Office Director |
|
2025-09-12 07:01 |
|
Return for Revision |
|
2025-09-12 07:01 |
|
Revised |
|
2025-09-25 22:40 |
 |
Publication Fee Transferred |
|
|
|
Second Decision by Editor |
|
2025-12-08 02:36 |
|
Second Decision by Editor-in-Chief |
|
|
|
Final Decision by Editorial Office Director |
|
2025-12-08 07:37 |
|
Articles in Press |
|
2025-12-08 07:37 |
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2026-01-09 05:56 |
|
Publish the Manuscript Online |
|
2026-01-16 11:31 |
| ISSN |
1007-9327 (print) and 2219-2840 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Gastroenterology & Hepatology |
| Manuscript Type |
Minireviews |
| Article Title |
Post-immunotherapy second-line strategies for hepatocellular carcinoma: State of the art and ongoing trials
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Sara Ascari, Rusi Chen, Andrea De Sinno, Bernardo Stefanini, Matteo Cescon, Matteo Serenari, Cristina Mosconi and Francesco Tovoli |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Francesco Tovoli, Associate Professor, MD, Division of Internal Medicine, Hepatobiliary and Immunoallergic Sciences, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Via Albertoni 15, Bologna 40138, Emilia-Romagna, Italy. francesco.tovoli2@unibo.it |
| Key Words |
Hepatocellular carcinoma; Immune checkpoint inhibitors; Second-line therapy; Post-immunotherapy progression; Tyrosine kinase inhibitors; Bispecific antibodies; Adoptive T-cell therapy; Chimeric antigen receptor-T cells; Treatment sequencing; Clinical trials |
| Core Tip |
Patients with hepatocellular carcinoma progressing after frontline immunotherapy represent an emerging clinical challenge. This review critically explores the current second-line strategies under investigation, including tyrosine kinase inhibitors, novel immune checkpoint inhibitor-based regimens, bispecific antibodies, and adoptive T-cell therapies. Most approaches are supported by strong biological rationale, although high-quality comparative data are still lacking. The multiplicity of ongoing trials underscores the need for a better understanding of resistance mechanisms and therapeutic sequencing. This review may assist clinicians and researchers in interpreting the evolving landscape and in identifying future directions for personalized, effective post-immunotherapy management. |
| Publish Date |
2026-01-16 11:31 |
| Citation |
Ascari S, Chen R, De Sinno A, Stefanini B, Cescon M, Serenari M, Mosconi C, Tovoli F. Post-immunotherapy second-line strategies for hepatocellular carcinoma: State of the art and ongoing trials. World J Gastroenterol 2026; 32(3): 111528 |
| URL |
https://www.wjgnet.com/1007-9327/full/v32/i3/111528.htm |
| DOI |
https://dx.doi.org/10.3748/wjg.v32.i3.111528 |
All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.
